<DOC>
	<DOC>NCT01941992</DOC>
	<brief_summary>The purpose of this study is to: - evaluate the activity of SAMITAL in reducing the incidence of severe mucositis in head-and-neck cancer patients undergoing chemo-radiotherapy. - assess tolerability of SAMITAL and the impact on patients reported outcomes.</brief_summary>
	<brief_title>Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Histologically proven squamous cell carcinomas of the headandneck Eligible primary tumor sites: oral cavity, oropharynx, larynx, hypopharynx Stage III or IV disease without evidence of distant metastases Patients candidate to definitive concurrent chemoradiotherapy or induction chemotherapy followed by chemoradiotherapy Age ≥ 18 years Karnofsky Performance Status ≥70 Life expectancy ≥6 months Able to swallow and retain oral medication Good state of dentition Patients must be available for treatment and followup Confirmation of adequate contraception use by the patient and/or partner Signed informed consent Previous radiotherapy of the oral cavity, and/or oropharynx, larynx, hypopharynx Serious comorbidities: uncontrolled heart disease, heart failure within 6 months prior to study participation, history of serious neurological and/or psychiatric abnormalities. Chronic administration of steroids or immunosuppressants Pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>head and neck</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>oral mucositis</keyword>
	<keyword>Chemo-radiotherapy</keyword>
</DOC>